Hologic — Nov 4, 2024 release

    Current Guidance       Guidance $   Reported % Increase (Decrease)   Constant Currency % Increase (Decrease)   Organic % Increase (Decrease)   Organic excluding COVID-19 % Increase (Decrease)   Fiscal 2025                           Revenue   $4,150 - $4,200   3.0% to 4.2%   2.3% to 3.5%   1.7% to 3.0%   3.4% to 4.7%   GAAP EPS   $3.53 - $3.63   6.3% to 9.3%                 Non-GAAP EPS   $4.25 - $4.35   4.2% to 6.6%                                              Q1 2025                           Revenue   $1,025 - $1,035   1.2% to 2.2%   0.4% to 1.4%   (0.2%) to 0.8%   1.8% to 2.8%   GAAP EPS   $0.81 - $0.84   (21.4%) to (18.4%)                 Non-GAAP EPS   $1.00 - $1.03   2.0% to 5.1%                 3 Use of Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this press release: constant currency revenues; organic revenues; organic revenues excluding COVID-19; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAAP net income margin; non-GAAP EPS; adjusted EBITDA; adjusted net leverage ratio and adjusted ROIC. Organic revenue for the fiscal fourth quarter of 2024 excludes the divested Blood Screening and SSI ultrasound imaging businesses and the acquired Endomagnetics business. Revenue from acquired businesses is generally included in organic revenue starting a year after the acquisition. Organic revenue excluding COVID-19 revenues is organic revenue less COVID-19 assay revenue, COVID-19 related sales of instruments, collection kits and ancillaries, COVID-19 related revenue from Diagenode and Mobidiag, as well as COVID-19 related license revenue, and revenues from discontinued products in Diagnostics. The Company defines its non-GAAP net income, EPS, and other non-GAAP financial measures